Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

for patients with mantle cell lymphoma (MCL) in remission following their initial treatment. The finding is from the phase 3 study EA4151, Rituximab With or Without Stem Cell Transplant in ...

Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

Q1 2025 Management View CEO Chad Robins highlighted a strong start to the year, with MRD revenue increasing 34% year-over-year, driven by clinical volumes, ASP improvements, and pharma sequencing. The ...

When he was first diagnosed with mantle cell lymphoma in New York in 2005, Cannella said he was told he had three to five years to live, so he opted for a clinical trial. That worked, for a while.

follicular lymphoma marginal zone lymphoma mantle cell lymphoma anemia that’s caused by myelodysplastic syndrome multiple myeloma Revlimid belongs to a class of drugs called thalidomide analogues.

Roche has secured approval from the EC for Columvi plus GemOx combo to treat adults with R/R diffuse large B-cell lymphoma (DLBCL).

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

In the BRIGHT study, bendamustine plus rituximab was evaluated as a first-line treatment for indolent non-Hodgkin lymphoma or mantle cell lymphoma compared with a standard rituximab-chemotherapy ...